dc.contributor.author | Beran, Roy | |
dc.contributor.author | Chow-Chuen, J | |
dc.date.accessioned | 2020-07-02T00:54:30Z | |
dc.date.available | 2020-07-02T00:54:30Z | |
dc.date.issued | 2019 | |
dc.identifier.uri | http://hdl.handle.net/10072/395073 | |
dc.description.abstract | Parkinson’s disease (PD) is a chronic, degenerative disease associated with motor complication that progressively affects quality of life and causes significant disability, either related to disease progression or treatment consequences. A number of guidelines provide treatment algorithms for selection of anti-Parkinsonian medications which suggest delaying the introduction of L-dopa due to the development of motor complications following prolonged exposure. This study examines the efficacy of the treatment model, adopted within a single Australian outpatient clinic, for polypharmacy (based on initiating L-dopa and complemented with later introduction of selegiline and subsequently a dopamine agonist and thence entacapone) for the treatment of Parkinson’s disease and to evaluate this approach to patient management. Of 152 patients with PD identified, 40 had been treated between 5 and 20 years and were analysed further to provide sufficient period to determine disease progression and treatment evaluation. Among the 40 long-term patients, 2.5% (1) of patients required a wheelchair and 15% (6) demonstrated motor complications. The majority of patients were coping well with their Parkinson’s disease and reported good quality of life. This study demonstrates that despite accepted guidelines, adopting a treatment algorithm based on early commencement of treatment with L-dopa and maintenance of low dose therapy with polypharmacy, appears beneficial both in the short term and the long-term management of patients with Parkinson’s disease. | |
dc.description.peerreviewed | Yes | |
dc.language | English | |
dc.language.iso | eng | |
dc.publisher | Chembio Publishers | |
dc.publisher.uri | https://chembiopublishers.com/CNNRIJ/volume.php?volumeId=44&issueId=78 | |
dc.relation.ispartofpagefrom | 1 | |
dc.relation.ispartofpageto | 9 | |
dc.relation.ispartofissue | 1 | |
dc.relation.ispartofjournal | Clinical Neuroscience & Neurological Research International Journal | |
dc.relation.ispartofvolume | 2 | |
dc.subject.fieldofresearch | Neurosciences | |
dc.subject.fieldofresearchcode | 3209 | |
dc.title | An independent clinical audit of an alternative treatment paradigm for the management of Parkinson’s Disease. | |
dc.type | Journal article | |
dc.type.description | C1 - Articles | |
dcterms.bibliographicCitation | Beran, R; Chow-Chuen, J, An independent clinical audit of an alternative treatment paradigm for the management of Parkinson’s Disease., Clinical Neuroscience & Neurological Research International Journal, 2019, 2 (1), pp. 1-9 | |
dc.date.updated | 2020-07-02T00:53:24Z | |
gro.hasfulltext | No Full Text | |
gro.griffith.author | Beran, Roy G. | |